TORONTO, ONTARIO--(Marketwire - April 11, 2011) - Arch Biopartners Inc ("Arch" or the "Company")(CNSX:ACH)(OTC:FOIFF) and its subsidiary Arch Cancer Therapeutics ("ACT") today announced Arch scientists have successfully completed proof of principle studies in the area of targeting brain tumour initiating cells.
This milestone is the result of the ongoing development work conducted by Arch scientists within their respective laboratories at the University of Calgary.
Following successful peer review, the Arch scientists intend to disclose the details of their results in an academic publication.
About Arch Cancer Therapeutics
ACT is an Alberta corporation wholly owned by Arch Biopartners. ACT's objective is to develop non-invasive diagnostic and therapeutic molecules for brain cancer. These molecules are specialized peptides proprietary to ACT that identify and target brain tumor initiating cells ("BTIC") and invasive brain cancer cells that are not normally seen using current state of the art diagnostic imaging techniques.
ACT intends to develop BTIC targeting diagnostic and therapeutic agents to meet significant unmet medical needs in the diagnosis and treatment of malignant gliomas of the brain.
About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.